Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
- 22 November 2023
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 44 (02) , 135-142
Abstract
Splanchnic or visceral vein thromboses (VVTs) are atypical thrombotic entities and include thrombosis of the portal vein, hepatic veins (Budd-Chiari syndrome), mesenteric veins, and splenic vein. All VVTs have in common high 30-day mortality up to 20% and it seems to be difficult to diagnose VVT early because of their rarity and their wide spectrum of unspecific symptoms. VVTs are often associated with myeloproliferative neoplasia, thrombophilia, and liver cirrhosis. VVT is primarily diagnosed by sonography and/or computed tomography. In contrast to venous thromboembolism, D-dimer testing is neither established nor helpful. Anticoagulation is the first-line therapy in patients with stable circulation and no evidence of organ complications. Anticoagulation improves significantly recanalization rates and stops the progress of thrombosis. Low-molecular-weight heparin, vitamin K antagonists, as well as direct-acting oral anticoagulants are possible anticoagulants, but it is noteworthy to be aware that all recommendations supporting the off-label use of anticoagulants are based on poor evidence and consist predominantly of case series, observational studies, or studies with small case numbers. When choosing a suitable anticoagulation, the individual risk of bleeding and thrombosis must be weighted very carefully. In cases of bleeding, bowel infarction, or other complications, the optimal therapy should be determined on a case-by-case basis by an experienced multidisciplinary team involving a surgeon. Besides anticoagulation, there are therapeutic options including thrombectomy, balloon angioplasty, stenting, transjugular placement of an intrahepatic portosystemic shunt, liver transplantation, and ischemic bowel resection. This article gives an overview of current diagnostic and therapeutic strategies.Keywords
This publication has 36 references indexed in Scilit:
- Associations of Antiphospholipid Antibodies With Splanchnic Vein ThrombosisMedicine, 2015
- Associations of Coagulation Factor V Leiden and Prothrombin G20210A Mutations With Budd–Chiari Syndrome and Portal Vein Thrombosis: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2014
- Vascular involvement in Behçet’s syndrome: a retrospective analysis of associations and the time courseRheumatology, 2014
- Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysisBlood, 2012
- Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd‐Chiari syndrome: A systematic review and meta‐analysis of observational studiesJournal of Gastroenterology and Hepatology, 2012
- Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein ThrombosisClinical Gastroenterology and Hepatology, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort studyJournal of Thrombosis and Haemostasis, 2011
- Survival and Recurrence in Patients With Splanchnic Vein ThrombosesClinical Gastroenterology and Hepatology, 2010
- Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-Up StudyHepatology, 2010